High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of rnultidrug resistance protein 4 (MRP4)

被引:54
作者
Cheung, Leanna [1 ]
Flemming, Claudia L. [1 ]
Watt, Fujiko [1 ]
Masada, Nanako [2 ]
Yu, Denise M. T. [1 ]
Huynh, Tony [1 ]
Conseil, Gwenaelle [3 ]
Tivnan, Amanda [1 ]
Polinsky, Alexander [4 ]
Gudkov, Andrei V. [5 ]
Munoz, Marcia A. [1 ]
Vishvanath, Anasuya [1 ]
Cooper, Dermot M. F. [2 ]
Henderson, Michelle J. [1 ]
Cole, Susan P. C. [3 ]
Fletcher, Jamie I. [1 ]
Haber, Michelle [1 ]
Norris, Murray D. [1 ]
机构
[1] Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia
[2] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England
[3] Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON, Canada
[4] OncoTartis Inc, Buffalo, NY USA
[5] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
基金
英国医学研究理事会; 加拿大健康研究院;
关键词
MRP4; inhibitor; ABCC4; Ceefourin; Multidrug resistance; High-throughput screening; MULTIDRUG-RESISTANCE; CONFERS RESISTANCE; EFFLUX TRANSPORTER; CYCLIC-NUCLEOTIDES; LEUKOTRIENE C-4; HUMAN PLATELETS; KIDNEY-CELLS; DRUGS; CAMP; NEUROBLASTOMA;
D O I
10.1016/j.bcp.2014.05.023
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette (ABC) transporter superfamily, is an organic anion transporter capable of effluxing a wide range of physiologically important signalling molecules and drugs. MRP4 has been proposed to contribute to numerous functions in both health and disease; however, in most cases these links remain to be unequivocally established. A major limitation to understanding the physiological and pharmacological roles of MRP4 has been the absence of specific small molecule inhibitors, with the majority of established inhibitors also targeting other ABC transporter family members, or inhibiting the production, function or degradation of important MRP4 substrates. We therefore set out to identify more selective and well tolerated inhibitors of MRP4 that might be used to study the many proposed functions of this transporter. Using high-throughput screening, we identified two chemically distinct small molecules, Ceefourin 1 and Ceefourin 2, that inhibit transport of a broad range of MRP4 substrates, yet are highly selective for MRP4 over other ABC transporters, including P-glycoprotein (P-gp), ABCG2 (Breast Cancer Resistance Protein; BCRP) and MRP1 (multidrug resistance protein 1; ABCC1). Both compounds are more potent MRP4 inhibitors in cellular assays than the most widely used inhibitor, MK-571, requiring lower concentrations to effect a comparable level of inhibition. Furthermore, Ceefourin 1 and Ceefourin 2 have low cellular toxicity, and high microsomal and acid stability. These newly identified inhibitors should be of great value for efforts to better understand the biological roles of MRP4, and may represent classes of compounds with therapeutic application. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:97 / 108
页数:12
相关论文
共 51 条
[1]   Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage [J].
Belinsky, Martin G. ;
Guo, Ping ;
Lee, Kun ;
Zhou, Feng ;
Kotova, Elena ;
Grinberg, Alex ;
Westphal, Heiner ;
Shchaveleva, Irina ;
Klein-Szanto, Andres ;
Gallo, James M. ;
Kruh, Gary D. .
CANCER RESEARCH, 2007, 67 (01) :262-268
[2]   Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma [J].
Burkhart, Catherine A. ;
Watt, Fujiko ;
Murray, Jayne ;
Pajic, Marina ;
Prokvolit, Anatoly ;
Xue, Chengyuan ;
Flemming, Claudia ;
Smith, Janice ;
Purmal, Andrei ;
Isachenko, Nadezhda ;
Komarov, Pavel G. ;
Gurova, Katerina V. ;
Sartorelli, Alan C. ;
Marshall, Glenn M. ;
Norris, Murray D. ;
Gudkov, Andrei V. ;
Haber, Michelle .
CANCER RESEARCH, 2009, 69 (16) :6573-6580
[3]   Transport of cyclic nucleotides and estradiol 17-β-D-glueuronide by multidrug resistance protein 4 -: Resistance to 6-mercaptopurine and 6-thioguanine [J].
Chen, ZS ;
Lee, K ;
Kruh, GD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) :33747-33754
[4]  
Chu XY, 1999, J PHARMACOL EXP THER, V288, P735
[5]  
CICCARONE V, 1989, CANCER RES, V49, P219
[6]   Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter [J].
Clark, R. ;
Kerr, I. D. ;
Callaghan, R. .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 149 (05) :506-515
[7]   Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present, and Future [J].
Cole, Susan P. C. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54, 2014, 54 :95-+
[8]   Multidrug Resistance Protein 4 (MRP4/ABCC4) Regulates cAMP Cellular Levels and Controls Human Leukemia Cell Proliferation and Differentiation [J].
Copsel, Sabrina ;
Garcia, Corina ;
Diez, Federico ;
Vermeulem, Monica ;
Baldi, Alberto ;
Bianciotti, Liliana G. ;
Russel, Frans G. M. ;
Shayo, Carina ;
Davio, Carlos .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (09) :6979-6988
[9]   Functional role of arginine 375 in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4) [J].
El-Sheikh, Azza A. K. ;
van den Heuvel, Jeroen J. M. W. ;
Krieger, Elmar ;
Russel, Frans G. M. ;
Koenderink, Jan B. .
MOLECULAR PHARMACOLOGY, 2008, 74 (04) :964-971
[10]   Inhibitory effect of the reversal agents V-104, GF120918 and pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport [J].
Evers, R ;
Kool, M ;
Smith, AJ ;
van Deemter, L ;
de Haas, M ;
Borst, P .
BRITISH JOURNAL OF CANCER, 2000, 83 (03) :366-374